Insmed Trading Volume Soars 79.26% to 1.76 Billion, Stock Price Drops 6.49% Amid FDA Setback, Ranks 494th in Market

On May 6, 2025, Insmed's trading volume reached 1.76 billion, marking a significant increase of 79.26% compared to the previous day, placing it at the 494th position in the day's stock market rankings. However, the stock price of Insmed (INSM) fell by 6.49%.

Insmed Incorporated, a biopharmaceutical company, has recently announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its drug candidate, brensocatib. The FDA has requested additional clinical data to support the efficacy and safety of the drug. This news has led to a decline in the company's stock price, as investors are concerned about the potential delay in the drug's approval and commercialization.

Insmed has also announced that it will be hosting a conference call to discuss the CRL and its plans moving forward. The company has stated that it is committed to working with the FDA to address the concerns raised in the CRL and to provide the additional data requested. Insmed has also reiterated its belief in the potential of brensocatib as a treatment for non-cystic fibrosis bronchiectasis (NCFBE) and its commitment to bringing this important therapy to patients in need.